RxDoctor Payments DataLook up a doctor →

James Appelbaum, MD

Neurology · Kansas City, KSNPI 1063426369

Payments from drug & device makers

$15,224in general payments, 2019–2025

Across 1,040 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • EMD Serono, Inc.$1K
  • Novartis$1K
  • Neurocrine Biosciences, Inc.$887
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)163$1,432
UCB, Inc.81$1,327
Teva Pharmaceuticals USA, Inc.109$1,185
EMD Serono, Inc.76$1,177
Novartis66$1,111
Neurocrine Biosciences, Inc.50$887
Amgen(2 entities)41$712
Biogen36$676
Jazz Pharmaceuticals Inc.30$598
Pfizer60$571
Bristol Myers Squibb32$508
Sanofi23$418
SK Life Science, Inc.19$321
Supernus Pharmaceuticals, Inc.25$318
Acadia Pharmaceuticals Inc17$317
Axsome Therapeutics, Inc.16$264
Lundbeck LLC16$244
Lilly USA, LLC14$237
Johnson & Johnson9$220
Eisai Inc.11$219
Argenx US, Inc.13$214
Sunovion Pharmaceuticals Inc.15$167
AstraZeneca(2 entities)8$144
Kyowa Kirin, Inc.8$139
Vanda Pharmaceuticals Inc.5$137
ANI Pharmaceuticals, Inc.7$131
Otsuka America Pharmaceutical, Inc.6$123
Harmony Biosciences LLC7$100
Genentech USA, Inc.5$85
MDD US Operations, LLC5$82
Sumitomo Pharma America, Inc.5$77
Livanova USA, Inc.4$73
Biohaven Pharmaceutical Holding Company Ltd.4$72
Biohaven Pharmaceuticals, Inc.4$69
Impel Pharmaceuticals Inc.3$59
Nevro Corp.3$57
Banner Life Sciences, LLC3$57
Azurity Pharmaceuticals, Inc.3$56
Scilex Pharmaceuticals Inc.3$55
Upsher-smith Laboratories LLC2$43
Greenwich Biosciences, Inc.2$42
Grifols USA, LLC2$39
Avanir Pharmaceuticals, Inc.3$39
Aprecia Pharmaceuticals, LLC2$37
Neurelis, Inc.2$32
Tanabe Pharma America, Inc.2$30
Travere Therapeutics, Inc.1$29
Currax Pharmaceuticals LLC2$27
Adamas Pharmaceuticals, Inc.2$24
Tersera Therapeutics LLC2$22
Resmed Corp1$22
Avadel CNS Pharmaceuticals, LLC1$21
Abbott1$19
Portola Pharmaceuticals, LLC1$19
Corium, LLC1$18
Vertex1$17
Mallinckrodt Hospital Products Inc.1$17
Alnylam Pharmaceuticals Inc.1$17
Boston Scientific1$16
GRT US Holding, Inc.1$15

How this compares

$15,224 in reported general payments places this provider in the 75th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas →

Medicare billing

Part B allowed, 2024
$92,080
Medicare patients
336
Services billed
2,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Kansas City

See the full list for Kansas →

Where these figures come from

Is this you, or does something look wrong? →